Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis

References

• Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281–291. doi:10.1080/1042819029000605311999559
   PubMed Web of Science ®Google Scholar
• Edenfield WJ, Gore SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol. 1999;26:21–34.
   PubMed Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126:319–321. doi:10.1182/blood-2014-10-55191125852056
   PubMed Web of Science ®Google Scholar
• Freyer CW, Gupta N, Wetzler M, Wang ES. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol. 2015;90:62–72. doi:10.1002/ajh.2386225284482
   PubMed Web of Science ®Google Scholar
• Lofgren C, Albertioni F, Paul C. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML. Ther Drug Monit. 2005;27:641–646.16175139
   PubMed Web of Science ®Google Scholar
• Hubeek I, Peters GJ, Broekhuizen R, et al. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica. 2006;91:17–23.16434366
   PubMed Web of Science ®Google Scholar
• Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009;109:2880–2893. doi:10.1021/cr900028p19476376
   PubMed Web of Science ®Google Scholar
• Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem. 2006;13:3165–3189.17168705
   PubMed Web of Science ®Google Scholar
• Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84:3429–3434.7949097
   PubMed Web of Science ®Google Scholar
• Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364–370. doi:10.1200/JCO.1992.10.3.3641346800
   PubMed Web of Science ®Google Scholar
• Gordon MS, Young ML, Tallman MS, et al. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res. 2000;24:871–875.10996206
   PubMed Web of Science ®Google Scholar
• Bao Y, Zhao J, Li ZZ. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. Clin Transl Oncol. 2018;20:870–880. doi:10.1007/s12094-017-1798-829181696
   PubMed Web of Science ®Google Scholar
• Wrzesien-Kus A, Robak T, Lech-Marańda E, et al. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol. 2003;71:155–162.12930315
   PubMed Web of Science ®Google Scholar
• Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39:121–129. doi:10.3109/1042819000905354510975390
   PubMed Web of Science ®Google Scholar
• Wrzesien-Kus A, Robak T, Wierzbowska A, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005;84:557–564. doi:10.1007/s00277-005-1046-015856358
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115–126. doi:10.1111/j.1600-0609.2007.00988.x18076637
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Martiat P, Mineur P, et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol. 1998;76:19–23.9486920
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 Available from: http://handbook.cochrane.org. Accessed January 5, 2019.
   Google Scholar
• Wells GA, Tugwell P, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2012 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 5, 2019.
   Google Scholar
• Xie CH, Wei M, Yang F-Y, et al. Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:3637–3648. doi:10.2147/CMAR.S16861030271212
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian HM, Ravandi F, et al. Cladribine combined with idarubicin and Ara-C (CLIA) as a frontline and salvage treatment for young patients (<65 yrs) with acute myeloid leukemia. Blood. 2018;132:4039.
   Web of Science ®Google Scholar
• Chen X, Weng J, Wang Y, et al. Combination of cladribine, cytarabine and topotecan (CLAT) for relapsed or refractory acute myeloid leukemia. Blood. 2015;126:4897.
   Web of Science ®Google Scholar
• Komrokji RS, Pinilla-Ibarz J, Yu D, et al. A phase II study of CLAG regimen in combination with imatinib mesylate in relapsed or refractory acute myeloid leukemia. Blood. 2011;118:2604. doi:10.1182/blood-2011-02-334870
   Web of Science ®Google Scholar
• Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic disease. J Clin Oncol. 2001;19:2804–2811. doi:10.1200/JCO.2001.19.11.280411387351
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10:1563–1569.8847890
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood. 1996;87:256–264.8547650
   PubMed Web of Science ®Google Scholar
• Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9:298–301. doi:10.3816/CLM.2009.n.05819717379
   PubMedGoogle Scholar
• Juliusson G, Lofgren C, Mollgard L, et al. No additional toxicity from cladribine (CdA) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase II study from the Leukemia Group of Middle Sweden (LGMS). Blood. 2001;98:518.
   Web of Science ®Google Scholar
• Hołowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter phase III study. Leukemia. 2004;18:989–997. doi:10.1038/sj.leu.240333614999298
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–2448. doi:10.1200/JCO.2011.37.128622508825
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597–601.8094016
   PubMed Web of Science ®Google Scholar
• Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989;49:6923–6928.2573423
   PubMed Web of Science ®Google Scholar
• Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990;86:1480–1488. doi:10.1172/JCI1148651700795
   PubMed Web of Science ®Google Scholar
• Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int J Immunopharmacol. 1986;8:999–1007.3492454
   PubMed Web of Science ®Google Scholar